The Korean Journal of Internal Medicine Vol. 29, No. 5 (Suppl. 1)
WCIM 2014 SEOUL KOREA 29
Slide Session
OS-HEM-05 Hematology
Gene Mutation Profi le in Chronic Myelogenous Leu- kemia BCR-ABL Positive Chronic Phase Patients Which Not Response to Imatinib Treatment in Dr.soetomo Teaching Hospital Surabaya Indonesia
Ugroseno Yudho BINTORO1, Made Putra SEDANA2, Agung SOSIAWAN3, Ami Ashariati PRAYOGO4, Soebandiri SOEBANDIRI5
Dr. Soetomo Hospital Airlangga University, Indonesia1, Dr. Soetomo Hospital Airlangga University, Indone- sia2, Human Genetic Division, Institute of Tropical Disease Airlangga University, Indonesia3, Dr. Soetomo Hospital Airlangga University, Indonesia4, Dr. Soetomo Hospital Airlangga University, Indonesia5 Background: To determine patterns of gene mutations in BCR-ABL tyrosine kinase in chronic myelogenous leukemia BCR-ABL positive chronic phase are not complete mo- lecular response to Imatinib treatment
Methods: Gene Mutation Analysis has been done in sixteen chronic myelogenous leu- kemia patients with BCR-ABL positive chronic phase who are not complete molecular response to Imatinib after 18 months treatment
Results: We found C944T gene mutation in 9 (56,25%) patients, T1052C gene mu- tation in 16 patients (100%), and T932C gene mutation in 13 patients (81,25%). One type of mutation found in one patient, two types of mutations in 6 patients, and 3 mutations in 9 patients.
Conclusions: No signifi cant effect of the C944T mutation and the T932C mutation with a single mutation of the tyrosine kinase drug resistance. There is infl uence of the T1052C single mutation to tyrosine kinase drug resistance.
OS-HEM-06 Hematology
Cardiotoxicity Effect of Doxorubicin in Non Hodgkin Lymphoma Patients Based on the Decrement Left Ven- tricel Ejection Fraction
Merlyna SAVITRI1, Rano ISMAIL2, Ugroseno Yudho BINTORO3, Rachmad ROMDONI4, Ami Ashariati PRAYOGO1
Hematology Oncology Division Department of Internal Medicine, Dr. Soetomo Hospital Airlangga Univer- sity, Indonesia1, Departement of Internal Medicine, Dr. Soetomo Hospital Airlangga University, Indonesia2, Hematology Oncology Division Department of Internal Medicine, Dr. Soetomo Hospital Airlangga Univer- sity, Indonesia3, Departement of Cardiology, Dr. Soetomo Hospital Airlangga University, Indonesia4, He- matology Oncology Division Department of Internal Medicine, Dr. Soetomo Hospital Airlangga University, Indonesia5
Background: To study the incidence of doxorubicin cardiotoxicity of in NHL patients who received CHOP (cyclophosphamide, doxorubicin, oncovin, prednisone) regimen in Dr.Soetomo Hospital, using echocardiography (EF, ejection fraction).
Methods: Fifteen NHL patients treated with CHOP were studied longitudinally. Echo- cardiography was done in patients at baseline, and after cumulative dose of doxoru- bicin = 200 and = 300 mg/m². Cardiotoxicity was defi ned as a decrease of LVEF = 10% from baseline or absolute LVEF < 50%.
Results: There was a decrease of mean LVEF after cumulative dose of doxorubicin = 200 mg/m² (2.87% from baseline, p>0,05) but without cardiotoxicity effect. There was a signifi cant decrease of mean LVEF of 6,36% from baseline (p<0,05) after cumulative dose of doxorubicin = 300 mg/m² with cardiotoxicity effect observed in 2 patients (13,3%). The decrement of LVEF of these 2 patients were 10.45% and 26.09%.
Conclusions: Cardiotoxicity effects were observed signifi cantly in NHL patients receiv- ing CHOP regimen.after cumulative doses of doxorubicin = 300 mg/m² (or after the 6th cycle)
OS-HEM-07 Hematology
Prognostic Impact of Beta-2 Microglobulin in Patients with Non-Gastric Marginal Zone Lymphoma
Changhoon YOO1, Dok Hyun YOON1, Shin KIM1, Chan-Sik PARK2, Jooryung HUH2, Sang-Wook LEE3, Jung Sun PARK1, Cheolwon SUH1
Asan Medical Center, University of Ulsan College of Medicine, Korea1, Asan Medical Center, University of Ulsan College of Medicine, Korea2, Asan Medical Center, University of Ulsan College of Medicine, Korea3 Background: Although serum Beta-2 microglobulin (B2M) has been suggested as a prognostic factor for several hematologic malignancies, this was rarely investigated in marginal zone lymphoma (NZL).
Materials: Between January, 2000, and May, 2013, a total of 270 patients with non-gastric (NG)-MZL were identifi ed from database of Asan Medical Center, Seoul, Korea. Among them, pretreatment baseline serum B2M was available in 204 patients.
Progression-free survival (PFS) and overall survival (OS) were compared according to the level of B2M with cut-off value of 2.5 mg/L.
Results: Median age of study population was 51 year-old (range, 16-81) and 85 (42%) patients were male. Thirty (15%) patients had nodal MZL and 174 (85%) had extranodal MALToma. B2M =2.5 mg/L was related with more adverse clinical features, such as poor performance status, =2 extranodal sites, advanced stage (III-IV), anemia, elevated LDH, bone marrow invasion, and higher IPI risk group. In univariate analysis, serum B2M (<2.5 mg/L vs =2.5 mg/L) was signifi cantly associated with PFS (p<0.001) and OS (p<0.001). In multivariate analysis including B2M and International Prognostic Index (IPI), serum B2M =2.5 mg/L was an independent adverse prognostic factor in terms of PFS (hazard ratio [HR]=3.7, 95% CI, 1.5-9.1; p=0.005) and OS (HR=7.5, 95%
CI, 1.7-32.7; p=0.008). In analysis including Korean MZL Prognostic Index (MZLPI: nod- al MZL, ECOG performance status =2 and advanced stage), B2MG =2.5 mg/L was also signifi cant for PFS (HR=3.5, 95% CI, 1.5-7.7; p=0.003) and OS (HR=7.3, 95% CI 1.9- 28.2; p=0.004).
Conclusion: In patients with NG-MZL, baseline serum B2M is a powerful prognostic factor for PFS and OS, independent of validated prognostic indexes, such as MZLPI and IPI.
OS-HEM-08 Hematology
Infl uence of Underlying Diseases and Vital Organ In- volvement in the Survival of 612 Patients with System- ic Amyloidosis (RAMYD-Geas-Semi)
Marta PEREZ DE LIS NOVO1, Pilar BRITO ZERÓN2, Luis Enrique CAJAMARCA3, Rosa JORDANA3, Roberto PÉREZ ALVAREZ4, Diego REAL DE ASÚA5, Sara BENITO CONEJERO6, Ferrán MARTÍNEZ VALLE7, Guadalupe FRAILE8, Iria VILLAVERDE9, Ester MONCLÚS10, Esther GONZÁLEZ GARCÍA11, Lina ACEVEDO AYALA12, Laura GONZÁLEZ VÁZQUEZ13, Jessica RUIZ IZQUIERDO14, Gloria DE LA RED14, Carlos SANTIAGO15, Elvira GONZÁLEZ VÁZQUEZ16, Luis INGLADA17, Angel ROBLES MARHUENDA18, Jorge Francisco GÓMEZ CEREZO19, Xavier BOSCH10, Manuel RAMOS CASALS2
CHUVI, Spain1, Hospital Clinic, Spain2, Parc Taulí Hospital, Spain3, Meixoeiro Hospital, Spain4, La Princ- esa Hospital, Spain5, Juan Ramón Jiménez Hospital, Spain6, Vall d’Hebrón Hospital, Spain7, Ramón y Cajal Hospital, Spain8, Xeral Hospital, Spain9, Hospital Clínic, Spain10, Cabueñes Hospital, Spain11, Gre- gorio Marañón Hospital, Spain12, POVISA Hospital, Spain13, Espíritu Santo Hospital, Spain14, Virgen De Las Nieves Hospital, Spain15, Complejo Hospitalario De Ourense, Spain16, Río Hortega Hospital, Spain17, La Paz Hospital, Spain18, Infanta Sofía Hospital, Spain19
Background: To analyze mortality and risk factors in a large series of patients with amyloidosis diagnosed in Internal Medicine Departments.
Methods: The national registry of amyloidosis patients (RAMYD) of the Study Group on Autoimmune Diseases of the Spanish Society of Internal Medicine included a total of 612 patients (331 men and 281 women, mean age at diagnosis of 64 years) on June 15, 2014.
Results: Information on the vital status of patients could be obtained in 523 cases, of which 325 (62%) died. Epidemiologically, there were no signifi cant differences with respect to gender, with a higher rate of mortality in older patients (67.28 vs 57.57 years, p<0.001). A higher mortality rate was observed in patients with chronic/degen- erative diseases in comparison with other etiologies (84% vs 59%, p<0.001). The high- est mortality rates were observed in patients with renal involvement (78% vs 59%, p<0.001) and cardiac involvement (78% vs 61%, p=0.001), while lower mortality rates were observed in patients with peripheral neuropathy (47% vs 70%, p<0.001) and skin
